Back to Aculeus
February 13, 2022
Aculeus is pleased to announce that it has recently signed agreements with L2 Preclinical Consulting and Charles River Laboratories to begin toxicological assessments of its STING agonist development candidates. This event marks an important next phase in the journey towards clinical assessment of our small molecules in patients with a variety of solid cancers and Aculeus is excited to be working with companies of the calibre of L2 and Charles River during this phase of its program
